Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
QMF149 150/80 μg · 1 trial · 1 indication
demonstrate the superiority of QMF149 150/80 microgram o.d. (in the evening) delivered via Concept1 compared with MF 200 microgram o.d. (in the evening) delivered via Twisthaler® in terms of trough FEV1 after 12 weeks of treatment in adults and adolescents. Forced Expiratory Volume in 1 second (FEV1) is the amount of air which can be forcibly exhaled from the lungs in the first second of a forced exhalation, measured by spirometry.
| Arm | Type | Description |
|---|---|---|
| QMF149 150/80 μg | EXPERIMENTAL | QMF149 150/80 microgram o.d. delivered via Concept1 |
| MF 200 µg | ACTIVE_COMPARATOR | MF 200 microgram o.d. delivered via Twisthaler® |
| Name | Type | Description |
|---|---|---|
| QMF149 150/80 μg | DRUG | QMF149 150/80 μg o.d via Concept1 |
| MF 200 μg | DRUG | MF 200 μg o.d. via Twisthaler® |
Inclusion Criteria: * Patients with a documented diagnosis of asthma for a period of at least 3 months prior to Screening Visit * Patients who have used low dose ICS , with or without controller (ie, LABA, Leukotriene Receptor Antagonist ) at stable dose for at least 1 month prior to Screening Visi...
QMF149 150/80 μg is an investigational small molecule being developed for the treatment of mild asthma. It is a fixed-dose combination product studied in patients with mild asthma, including adolescents aged 12 years and older. The drug is administered via inhalation and is currently in Phase 3 clinical development.
QMF149 150/80 μg is a combination product containing two active ingredients: a long-acting beta-agonist and an inhaled corticosteroid. It works by relaxing airway muscles and reducing inflammation in the lungs, which helps improve asthma control. The specific molecular targets are the beta-2 adrenergic receptor and the glucocorticoid receptor.
QMF149 150/80 μg is developed by Novartis AG, a multinational pharmaceutical company headquartered in Basel, Switzerland. Novartis trades on the New York Stock Exchange under the ticker symbol NVS. The company is conducting clinical trials to evaluate the safety and efficacy of this investigational asthma treatment.
QMF149 150/80 μg is in Phase 3 clinical development for mild asthma. It is an investigational drug, meaning it has not yet been approved by regulatory authorities. A Phase 3 trial has been completed, and the drug is being evaluated for its efficacy and safety compared to an active control in patients with mild asthma.
QMF149 150/80 μg was studied in a Phase 3 clinical trial registered as NCT02892344. This completed trial, titled 'Study of QMF149 (150/80 µg) Compared With MF Twisthaler® (200 µg) in Patients With Asthma,' enrolled 802 participants with mild asthma across multiple countries. The trial was randomized, double-blind, and active-controlled.
QMF149 150/80 μg is not the same as MF Twisthaler. In the clinical trial NCT02892344, QMF149 150/80 μg was compared against MF Twisthaler (200 µg), which served as the active control. QMF149 is a fixed-dose combination product, while MF Twisthaler contains a single active ingredient, mometasone furoate, a corticosteroid.